Ughi e Nunziante Studio Legale, assisted Equasens Group, a leading healthcare software publisher, listed on Euronext Paris (Compartment – A) in the acquisition – in partnership with ARZ Haan – of the entire share capital of the German company ADV. Following the transaction, ADV become PHARMAGEST Germany through a holding-company 94%-held by Equasens and 6%-held by ARZ Haan.
This operation marks a significant milestone in Equasens’ growth strategy, as the company was already present in Germany through its subsidiary MultiMeds, focusing on medication compliance.
Ughi e Nunziante was appointed by Equasens for managing the ADV acquisition-related aspects and the joint venture agreement with ARZ Haan, with a team comprising Partner Amon Airoldi and Associate Pietro Pastorello. The firm also collaborated with Wuertenberger for legal due diligence and German law aspects, represented by Partner Marc Winstel, and with Mundhenke & Partner for tax due diligence, led by Partners Thomas Habermann and Gunnar Goldenbaum.
Equasens also sought legal assistance from Martini Manna Avvocati, represented by Partner Rocco Lanzavecchia, for intellectual property and information technology matters.
